PHYSIOLOGIC SODIUM CHLORIDE SOLUTION
Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1
Ever Neuro Pharma GmbHSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adrenomedullin National Cerebral and Cardiovascular Center, Japan | Phase 2 | B |
Hov-12020 Hovid Berhad | Phase 2 | B |
Dabigatran S. Andrea Hospital | Phase 2 | CCC |
Cerebrolysin Ever Neuro Pharma GmbH | Phase 2 | CCC |
Fremanezumab Mayo Clinic | Phase 2 | CCC |
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Mayo Clinic | Phase 1/2 | CCC |
Same molecule, other indications
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →